Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre study to characterize the safety and efficacy of the human
anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous
Nephropathy (newly diagnosed/relapsed/refractory)